NRIX - Nurix Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$32.20
DETAILS
HIGH:
$36.00
LOW:
$28.00
MEDIAN:
$32.00
CONSENSUS:
$32.20
UPSIDE:
84.00%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| Revenue | 84.0 | 54.5 | 77.0 | 38.6 | 29.8 | 17.8 | 31.1 | 37.4 |
| Cost of Revenue | 18.9 | 221.6 | 189.1 | 184.5 | 116.4 | 66.5 | 45.0 | 40.5 |
| Gross Profit | 65.1 | (167.1) | (112.2) | (145.9) | (86.7) | (48.7) | (13.9) | (3.1) |
| Operating Expenses | ||||||||
| R&D Expenses | 308.2 | 221.6 | 189.1 | 184.5 | 116.4 | 66.5 | 45.0 | 40.5 |
| SG&A Expenses | 52.7 | 45.9 | 42.9 | 38.0 | 31.2 | 16.3 | 8.3 | 6.7 |
| Other Expenses | (10.1) | (221.6) | (189.1) | (184.5) | (116.4) | (66.5) | (45.0) | (40.5) |
| Operating Expenses | 350.8 | 45.9 | 42.9 | 38.0 | 31.2 | 16.3 | 8.3 | 6.7 |
| Operating Income | ||||||||
| Operating Income | (285.7) | (213.0) | (155.1) | (183.9) | (117.9) | (65.0) | (22.2) | (9.7) |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 22.0 | 19.7 | 11.1 | 3.5 | 0.8 | 1.2 | 0.8 | 0.8 |
| Profitability | ||||||||
| EBITDA | (244.8) | (205.0) | (148.9) | (179.7) | (115.9) | (62.8) | (19.9) | (6.8) |
| EBIT | (263.7) | (213.0) | (155.1) | (183.9) | (117.9) | (65.0) | (22.2) | (9.7) |
| Income Before Tax | (263.7) | (193.3) | (143.9) | (180.4) | (117.1) | (63.8) | (21.5) | (8.9) |
| Income Tax Expense | 0.8 | 0.3 | 0 | 0 | 0.1 | (20.5) | 0.2 | 0.5 |
| Net Income | (264.5) | (193.6) | (143.9) | (180.4) | (117.2) | (43.2) | (21.7) | (9.4) |
| Per Share Data | ||||||||
| EPS (Basic) | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 | -0.56 | -0.59 |
| EPS (Diluted) | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 | -0.56 | -0.59 |
| Shares Outstanding | 86.7 | 67.1 | 54.3 | 48.6 | 42.9 | 15.7 | 38.8 | 16.1 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||
| Cash & Cash Equivalents | 247.0 | 110.0 | 54.6 | 64.5 | 80.5 | 119.4 | 34.8 | 25.6 |
| Short-Term Investments | 346.0 | 499.6 | 233.3 | 244.7 | 215.2 | 161.8 | 2.9 | 13.4 |
| Net Receivables | 0 | 1.5 | 0.8 | 1.1 | 6.2 | 11.3 | 0 | 0 |
| Inventory | 0 | 0 | 0 | (1.1) | 0 | 0 | 0 | 0 |
| Other Current Assets | 13.9 | 8.3 | 6.8 | 9.3 | 0.9 | 0 | 0 | 0 |
| Total Current Assets | 606.8 | 619.4 | 295.5 | 318.4 | 311.1 | 298.4 | 39.4 | 40.7 |
| Non-Current Assets | ||||||||
| Property, Plant & Equipment | 73.0 | 45.9 | 48.0 | 29.5 | 25.3 | 6.7 | 3.9 | 4.4 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 7.4 | 63.9 | 137.5 | 90.9 | 0.5 | 0.2 |
| Other Non-Current Assets | 8.3 | 4.1 | 4.7 | 4.9 | 3.1 | 0.3 | 0.3 | 0.2 |
| Total Non-Current Assets | 81.3 | 50.0 | 60.1 | 98.3 | 165.7 | 97.9 | 4.7 | 4.7 |
| Total Assets | 688.1 | 669.3 | 355.6 | 416.8 | 476.8 | 396.3 | 44.0 | 45.4 |
| Current Liabilities | ||||||||
| Account Payables | 11.2 | 11.5 | 6.4 | 5.1 | 6.7 | 3.4 | 1.6 | 1.3 |
| Short-Term Debt | 0 | 0 | 7.5 | 5.5 | 3.8 | 0 | 0 | 0 |
| Deferred Revenue | 17.6 | 38.4 | 48.1 | 37.6 | 41.2 | 32.8 | 9.6 | 28.4 |
| Other Current Liabilities | 23.6 | 18.9 | 0.8 | 9.1 | 5.7 | 2.6 | 1.2 | 0.7 |
| Total Current Liabilities | 86.5 | 95.9 | 87.0 | 70.7 | 66.3 | 44.5 | 16.1 | 32.8 |
| Non-Current Liabilities | ||||||||
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0.8 | 1.7 | 1.2 |
| Total Non-Current Liabilities | 62.9 | 46.5 | 68.1 | 42.4 | 68.2 | 61.5 | 85.6 | 49.4 |
| Total Liabilities | 149.4 | 142.3 | 155.1 | 113.1 | 134.5 | 106.1 | 53.6 | 34.0 |
| Stockholders' Equity | ||||||||
| Common Stock | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Retained Earnings | (1,003.2) | (738.8) | (545.2) | (401.3) | (220.9) | (103.7) | (60.5) | (38.8) |
| Accumulated Other Comprehensive Income | 0.1 | 0.1 | (0.7) | (4.3) | (0.6) | 0.1 | (0.0) | (0.0) |
| Total Stockholders' Equity | 538.7 | 527.0 | 200.5 | 303.7 | 342.3 | 290.3 | (57.7) | (36.8) |
| Total Liabilities & Equity | 688.1 | 669.3 | 355.6 | 416.8 | 476.8 | 396.3 | 44.0 | 45.4 |
| Debt Metrics | ||||||||
| Total Debt | 55.7 | 28.3 | 30.6 | 12.0 | 13.0 | 0 | 0 | 0 |
| Net Debt | (191.2) | (81.7) | (24.0) | (52.5) | (67.5) | (119.4) | (34.8) | (25.6) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | (264.5) | (193.6) | (143.9) | (180.4) | (117.2) | (43.2) | (21.7) | (9.4) |
| Depreciation & Amortization | 18.9 | 16.4 | 13.7 | 10.8 | 6.1 | 2.2 | 2.4 | 3.0 |
| Stock-Based Compensation | 38.0 | 33.9 | 33.7 | 28.1 | 15.8 | 4.3 | 0.5 | 0.4 |
| Change in Working Capital | (31.6) | (18.4) | 20.1 | (19.0) | 9.1 | 36.4 | 19.5 | (25.3) |
| Other Non-Cash Items | (10.2) | (11.0) | (4.9) | 0.6 | 1.8 | 0.3 | (0.1) | (0.0) |
| Operating Cash Flow | (249.5) | (172.6) | (81.4) | (159.8) | (84.4) | (0.1) | 0.6 | (31.7) |
| Investing Activities | ||||||||
| Capital Expenditure | (14.0) | (9.3) | (8.4) | (12.2) | (5.7) | (4.6) | (1.7) | (1.6) |
| Acquisitions | 0 | 0 | 0 | (39.4) | 102.6 | 249.9 | (10.1) | 0.0 |
| Purchases of Investments | (455.7) | (708.0) | (246.3) | (239.4) | (348.5) | (275.2) | (9.4) | (12.9) |
| Sales/Maturities of Investments | 617.5 | 459.5 | 323.0 | 278.8 | 245.9 | 25.4 | 19.5 | 54.5 |
| Other Investing Activities | 0 | 0 | 0 | 39.4 | (102.6) | (249.9) | 10.1 | 0 |
| Investing Cash Flow | 147.9 | (257.7) | 68.3 | 27.2 | (108.3) | (254.4) | 8.5 | 40.0 |
| Financing Activities | ||||||||
| Net Debt Issuance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | (0.0) | (0.0) | (0.0) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 7.2 | 0 | 97.8 | 3.7 | 1.0 | 0 | 0 |
| Financing Cash Flow | 238.6 | 485.7 | 3.2 | 117.2 | 153.9 | 339.0 | 0.1 | 0.5 |
| Cash Position | ||||||||
| Net Change in Cash | 137.0 | 55.4 | (9.8) | (15.4) | (38.7) | 84.5 | 9.2 | 8.8 |
| Cash at Beginning | 110.0 | 55.5 | 65.4 | 80.8 | 119.5 | 35.0 | 25.8 | 16.9 |
| Cash at End | 247.9 | 110.9 | 55.5 | 65.4 | 80.8 | 119.5 | 35.0 | 25.8 |
| Free Cash Flow | (263.5) | (181.9) | (89.8) | (172.1) | (90.0) | (4.6) | (1.1) | (33.3) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 84.0 | 54.5 | 77.0 | 38.6 | 29.8 | 17.8 | 31.1 | 37.4 |
| Gross Profit | 65.1 | (167.1) | (112.2) | (145.9) | (86.7) | (48.7) | (13.9) | (3.1) |
| Operating Income | (285.7) | (213.0) | (155.1) | (183.9) | (117.9) | (65.0) | (22.2) | (9.7) |
| Net Income | (264.5) | (193.6) | (143.9) | (180.4) | (117.2) | (43.2) | (21.7) | (9.4) |
| EPS (Diluted) | -3.05 | -2.88 | -2.65 | -3.71 | -2.73 | -2.76 | -0.56 | -0.59 |
| Balance Sheet | ||||||||
| Cash & Equivalents | 247.0 | 110.0 | 54.6 | 64.5 | 80.5 | 119.4 | 34.8 | 25.6 |
| Total Assets | 688.1 | 669.3 | 355.6 | 416.8 | 476.8 | 396.3 | 44.0 | 45.4 |
| Total Debt | 55.7 | 28.3 | 30.6 | 12.0 | 13.0 | 0 | 0 | 0 |
| Stockholders' Equity | 538.7 | 527.0 | 200.5 | 303.7 | 342.3 | 290.3 | (57.7) | (36.8) |
| Cash Flow | ||||||||
| Operating Cash Flow | (249.5) | (172.6) | (81.4) | (159.8) | (84.4) | (0.1) | 0.6 | (31.7) |
| Capital Expenditure | (14.0) | (9.3) | (8.4) | (12.2) | (5.7) | (4.6) | (1.7) | (1.6) |
| Free Cash Flow | (263.5) | (181.9) | (89.8) | (172.1) | (90.0) | (4.6) | (1.1) | (33.3) |